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measurers was 0.816 (p  0.0001). Cost/QALY exceeded cost/life-year in 61% of cases 
whereas cost/life-year exceeded cost/QALY in 39% of cases. In 124 (84%) of com-
parisons, both cost/QALY and cost/life-year ratios were below a pre-speciﬁed thresh-
old (e.g., $50,000 per QALY or life-year). In 14 (10%) of cases, adjusting for quality 
of life resulted in a ratio that crossed the $50,000 value, whereas in 4(3%) the cost/
QALY ratio crossed the $100,000 threshold. CONCLUSIONS: Adjusting life years 
for HRQL does not substantively affect cost per life year ratios for the vast majority 
of published cancer interventions in our sample. The results suggest that the method 
used for quality adjusting or even quality adjusting at all may not matter for cost-
effectiveness analyses of life saving cancer interventions. The results could differ for 
cancer interventions that have large impacts on patients’ HRQoL.
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OBJECTIVES: The assessment of economic implications, both for individualized 
breast cancer (BC) prevention and for public health policy, of ﬁndings concerning the 
risk of BC cancer in women with CHEK2 heterozygosity. METHODS: Cost-
 effectiveness analysis of genotyping every women at CHEK2 and offering—on the 
basis of her BC risk proﬁle—a personalized screening programme in which the starting 
age would vary, versus present strategy, was perfomed using modelling technique. 
Two scenarios were compared: (A) DNA CHEK2 test in all women, screening strategy 
beginning at 25 years of age only in CHEK2-positive women (1.2%) and standard 
screening strategy (beginning at 50 years) in the remained population; (B) without 
DNA CHEK2 test, in all women standard screening strategy. Data on life expectancy, 
BC risk, efﬁcacy of screening strategy and medical costs were obtained from published 
literatures. The cohort simulation started with 25-year-old women and projected 
direct medical costs and outcomes over patients lifetimes. Effectiveness was measured 
as life years gained (LYG). Only direct medical costs (BC screening and treatment) 
were included, assessed from health care payer perspective and reported in PLN (1 
EUR  4.5 PLN in 2009). 5% and 3.5% discount rate was used for cost and effective-
ness, respectively. RESULTS: The total lifetime costs/patient were estimated to be 
2223.85 PLN (discounted: 644.84 PLN) in (A) and 1998.20 PLN (discounted: 
430.15 PLN) in (B). The total LYG generated with scenario (A) were 50.958 vs. 
50,939 with scenario (B) (without discounting) and 23,170 vs. 23,165 (discounted), 
respectively. This results in ICER for (A) of 11,862 PLN/LYG (without discounting) 
and 41,865 PLN/LYG (discounted). Results were robust to sensitivity analyses. CON-
CLUSIONS: The use of CHEK2genotyping and pesonalized BC screening improves 
survival compared to standard strategy and considering the suggested threshold for 
cost-effectiveness in Poland (80,000 PLN/LYG in 2008), is cost-effective in the Polish 
health care system.
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OBJECTIVES: Sorafenib is an oral multi-kinase inhibitor that targets tumour cell 
proliferation and tumour angiogenesis. In the TARGET study (phase III trial), 
sorafenib plus best supportive care (BSC) signiﬁcantly prolonged progression-free 
survival (PFS) compared with BSC alone in patients with unresectable and/or meta-
static renal cell carcinoma (mRCC). The objective of this study was to assess the 
cost-effectiveness of sorafenib plus BSC versus BSC alone in mRCC patients in Turkey. 
The study was undertaken from a Turkish health care payer perspective. METHODS: 
A Markov model was developed to estimate costs and outcomes associated with 
sorafenib  BSC and BSC alone. The model tracked patients with mRCC through 
three health states: PFS, disease progression and death. PFS and survival were extrapo-
lated based on patient level trial data (TARGET) over a patients’ lifetime. Health 
effects were expressed as life years gained (LYG). Incidence of adverse events (AEs) 
were also obtained from TARGET. Resource utilization data were obtained via expert 
clinical opinion and included physician visits, hospitalizations, monitoring, treatment 
of AEs, etc. Unit costs were taken from the Social Security Institution’s ofﬁcial price 
list. Costs and effects were evaluated over a lifetime and discounted at 3%. Results 
were presented as incremental cost/LYG. Deterministic and probabilistic sensitivity 
analyses were also conducted. RESULTS: The incremental survival beneﬁt with 
sorafenib was 1.269 LYG. The lifetime cost per patient was 4,080 TL for BSC and 
47,665 TL for sorafenib  BSC. The incremental cost-effectiveness ratio of sorafenib 
 BSC was 34,342 TL per LYG compared with BSC alone. Sensitivity analyses con-
ﬁrmed the robustness of the model results. CONCLUSIONS: Compared with BSC 
alone, sorafenib  BSC is a cost-effective therapy option in the treatment of unresect-
able and/or metastatic renal cell carcinoma (mRCC) patients in Turkey.
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OBJECTIVES: To compare costs and health beneﬁts of two therapeutic options for 
the ﬁrst line treatment of chemotherapy naïve patients with locally advanced or meta-
static non-small cell lung cancer (NSCLC)—gemcitabin/cisplatin versus pemetrexed/
cisplatin. METHODS: A lifetime 3-week cycle Markov model was developed and 
adapted for Portugal in order to estimate costs per life year (LY) and per quality 
adjusted life year (QALY) gained for patients with adenocarcinoma and large cell car-
cinoma histology. The model considers three disease states—stable, response, progres-
sion—and two treatment phases—during and after ﬁrst line treatment. Patients may 
suffer from adverse events such as neutropenia and febrile neutropenia; fatigue; diar-
rhoea; nausea and vomiting; bleeding; anaemia; and thrombocytopenia. The clinical 
inputs to the economic model were obtained from phase 3 pivotal trial. Direct medical 
costs were estimated according to both the Society’s and the NHS perspectives. 
A Delphi panel was conducted in order to estimate resource consumption. Unit costs 
were derived from ofﬁcial sources. RESULTS: Patients treated with pemetrexed 
have a discounted expected LY 1.226 compared to 1.104 of those treated with gem-
citabine. Due to the low quality of life of the population considered, QALY are 0.655 
and 0.595, respectively. Incremental costs with pemetrexed are below a3,900 for both 
perspectives due to its higher price and to a larger consumption of best supportive care. 
Therefore, the incremental cost per LY gained is a31,154 for the Society (a63,859 per 
QALY) and a30,950a for the NHS (a63,441a per QALY). Sensitivity analysis shows 
that these ﬁndings are only affected by the assumptions adopted on the mean body 
surface area, drug wastage and overall survival. CONCLUSIONS: The incremental 
cost per LY of pemetrexed is acceptable. However, the incremental cost per QALY is 
higher than usual thresholds due to the low basal quality of life of the population.
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OBJECTIVES: The aim of this study is to evaluate general practitioners’ prescription 
(GPs) of different Proton Pump Inhibitors (PPIs) in the period between 2005 to 2008. 
METHODS: Analysis has been performed on a database of 99 medical practitioners 
that have managed an average of 150.000 inhabitants. We evaluate the PPIs prescrip-
tions from January 2005 to December 2008. Evaluations performed are the following: 
1) PPI prescription (total and separately for lansoprazole, esomeprazole, pantoprazole, 
rabeprazole, and omeprazole); 2) prevalence of the reimbursement purpose (Gastro-
protection—G; Acid-Related Disease—ARD); 3) prevalence of patients with ARD 
categorized on the basis of PPI prescriptions as drugs box/year (1–3 short treat-
ment—ST; 4–11 long treatment—LT; 12 very long treatment—VLT). Data were 
expressed as Compound Annual Growth Rate (CAGR). RESULTS: The total volume 
of PPI’s prescribing increased progressively over the 4 years (CAGR 15%). The 
growth for each molecule was: L 42%; E 11%; P 16; R 3%; O 1%. The reim-
bursement purpose was signiﬁcantly higher for G (CAGR 41%) than for ARD 
(CAGR 6%; p  0.01). We found an increase of ARD patients with VLT with a sig-
niﬁcant highest CAGR (ST 3.9%, LT 4.8%, VLT 7.4%; p  0.01). PPI prescription 
showed a highest CAGR for L in all patients (27%), while the lowest one was for O 
in VLT patients (-9%). CONCLUSIONS: Generic PPIs has unexpectedly increased the 
prescription of whole drug class during the period 2005–2008. We observed a marked 
increase in a very long duration PPI treatment for ARD that caused a relevant resource 
consumption. Our data suggest that the appropriateness of PPI prescription after 
generic PPI introduction should be carefully monitored to distinguish between cost-
effective from cost-ineffective PPI treatment.
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OBJECTIVES: To estimate the impact of cost-containment reforms on R&D indica-
tors of pharmaceutical ﬁrms in eight countries and draw policy recommendations. 
METHODS: The average treatment effect on the treated is econometrically estimated 
with difference-in-difference (DiD); before-after comparisons; DiD with correlated 
random trend and a synthetic control group; kernel and nearest neighbour matching 
DiD methods. RESULTS: This study estimates short-term effects of recent regulatory 
changes in public health care on ﬁnancial indicators related to pharmaceutical R&D 
in Denmark, France, Germany, Italy, Japan, Norway, Sweden, and the US. The dataset 
represents a panel of ﬁnancial statements of 1306 pharmaceutical ﬁrms for the period 
1997–2007. The evaluated indicators include R&D expenditure, R&D expenditure 
to total revenue, cash ﬂow, gross margin, and price-to-book ratio. The national 
pharmaceutical expenditures, population, availability of credit for the private sector, 
